Status:
COMPLETED
Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Dyskinesias
Eligibility:
All Genders
8+ years
Brief Summary
Heterozygous mutations in the ADCY5 gene cause involuntary early-onset hyperkinetic movements. In addition, patients may have associated psychiatric disorders.There is currently no treatment. As the p...
Detailed Description
Heterozygous mutations in the ADCY5 gene cause involuntary early-onset hyperkinetic movements. The phenotype combines chorea, dystonia and / or myoclonus with frequent facial involvement, axial hypoto...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Proven genetic diagnosis of ADCY5-related dyskinesia
- Caffeine intake
- Non opposition by the patient or the legal representatives if the patient is a minor.
- No Exclusion Criteria.
Exclusion
Key Trial Info
Start Date :
May 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 6 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04351360
Start Date
May 15 2020
End Date
May 6 2021
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Département de Neurologie Groupe Hospitalier Pitié-Salpêtrière
Paris, France, 75651 PARIS Cedex 13